Abiopharma

ALHC INVESTOR ALERT: Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors Urged to Contact Hagens Berman; Investigation Opened Following Disappointing Second-Quarter Results and Whistleblower Allegations

Marqeta Expands Collaboration with Google to Launch New Offering in Wallet for Kids

Georgia Power Generation employees keep reliable energy flowing throughout the hottest days of summer

Bronstein, Gewirtz & Grossman LLC Urges iTonic Holdings Ltd. f/k/a Pheton Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

SEI Launches ANGU ETF, Bringing Factor Research to Traditional Index Exposure

Mortgage Rates Average 6.69%

The Wizard of Oz at Sphere Celebrates One Year of Redefining Immersive Storytelling

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

LECTRA : Déclaration mensuelle du nombre total dactions et de droits de vote composant le capital social (au 31 juillet 2026)

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

LECTRA: Monthly declaration of the total number of shares and voting rights composing the companys capital (at July 31st, 2026)

Bronstein, Gewirtz & Grossman LLC Urges Avis Budget Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Chemed Corporation Declares Quarterly Dividend of 70 Cents

Theriva™ Biologics anuncia que se ha administrado la primera dosis a un paciente en el ensayo clínico VIRAGE2 de Fase IIa, destinado a evaluar una administración más frecuente de VCN-01 (zabilugene almadenorepvec) en pacientes en tratamiento de primera línea con adenocarcinoma ductal pancreático metastásico